Innate Pharma Sa Financials
Innate Pharma Sa (IPHA) reported $50.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Reported scale is still modest, with $50M of annual revenue carrying most of the observable operating story.
With$50M of revenue across 93.7M shares, revenue per share is only about$0.53 , so the latest filing shows a business that has reached reported sales but not yet much economic density on a per-share basis. That matters because per-share scale is the raw material from which margins and cash generation eventually become meaningful, and this record does not yet show those layers.
Because cash conversion, profitability, and balance-sheet fields are absent in this annual snapshot, the key unanswered question is whether that
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We are recalculating Innate Pharma Sa's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Innate Pharma Sa generated $50.0M in revenue in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
IPHA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 |
|---|---|
| Revenue | $50.0M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
Similar Companies
Where Innate Pharma Sa Ranks
Frequently Asked Questions
What is Innate Pharma Sa's annual revenue?
Innate Pharma Sa (IPHA) reported $50.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.